| Name | Glenhaven |
|---|---|
| Location | 612 E Oak St, Glenwood City, Wisconsin |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 44 |
| Occupancy Rate | 63.18% |
| Medicare ID (CCN) | 525602 |
| Legal Business Name | Glenhaven, Inc. |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1700809126 |
| Organization Name | GLENHAVEN, INC. |
| Address | 612 E Oak St, Glenwood City, WI 54013 |
| Phone Number | 715-265-4555 |
News Archive
One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic Institute are endeavoring to solve this problem by investigating new methods for bypassing the blood-brain barrier and combating the spread of brain cancer.
Synovis Life Technologies, Inc., has received Food and Drug Administration 510(k) marketing clearance for its Flow Coupler®, an innovative extension of the company's well-established Microvascular Anastomotic Coupler used in several surgical procedures to connect small blood vessels more quickly and with equal or greater reliability than hand suturing. The Flow Coupler incorporates Doppler technology to immediately measure blood flow after connecting the small blood vessels.
This week a senator followed House lawmakers' lead by introducing a bill that would let the children of federal employees remain on their parents' health insurance until age 26, starting this year. Under the health reform law President Obama signed in March, the cutoff age would have increased from 22 to 26 in January 2011 for Federal Employees Health Benefits Program participants, due to laws that prevent the Office of Personnel Management from making midyear changes.
More than 40 years after beta blockers were first used clinically, scientists can finally get a detailed, three-dimensional look at the drugs' molecular target - the beta2-adrenergic receptor.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic Institute are endeavoring to solve this problem by investigating new methods for bypassing the blood-brain barrier and combating the spread of brain cancer.
Synovis Life Technologies, Inc., has received Food and Drug Administration 510(k) marketing clearance for its Flow Coupler®, an innovative extension of the company's well-established Microvascular Anastomotic Coupler used in several surgical procedures to connect small blood vessels more quickly and with equal or greater reliability than hand suturing. The Flow Coupler incorporates Doppler technology to immediately measure blood flow after connecting the small blood vessels.
This week a senator followed House lawmakers' lead by introducing a bill that would let the children of federal employees remain on their parents' health insurance until age 26, starting this year. Under the health reform law President Obama signed in March, the cutoff age would have increased from 22 to 26 in January 2011 for Federal Employees Health Benefits Program participants, due to laws that prevent the Office of Personnel Management from making midyear changes.
More than 40 years after beta blockers were first used clinically, scientists can finally get a detailed, three-dimensional look at the drugs' molecular target - the beta2-adrenergic receptor.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $10000 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.04 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.11 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 42.42 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.48 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 6.09 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.72 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.96 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.16 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 78.48 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 33.85 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 11.3 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.49 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 79.6 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 96.43 | 82.93 |
News Archive
One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic Institute are endeavoring to solve this problem by investigating new methods for bypassing the blood-brain barrier and combating the spread of brain cancer.
Synovis Life Technologies, Inc., has received Food and Drug Administration 510(k) marketing clearance for its Flow Coupler®, an innovative extension of the company's well-established Microvascular Anastomotic Coupler used in several surgical procedures to connect small blood vessels more quickly and with equal or greater reliability than hand suturing. The Flow Coupler incorporates Doppler technology to immediately measure blood flow after connecting the small blood vessels.
This week a senator followed House lawmakers' lead by introducing a bill that would let the children of federal employees remain on their parents' health insurance until age 26, starting this year. Under the health reform law President Obama signed in March, the cutoff age would have increased from 22 to 26 in January 2011 for Federal Employees Health Benefits Program participants, due to laws that prevent the Office of Personnel Management from making midyear changes.
More than 40 years after beta blockers were first used clinically, scientists can finally get a detailed, three-dimensional look at the drugs' molecular target - the beta2-adrenergic receptor.
› Verified 3 days ago